Details of the Drug Reposition

General Information of This Drug (ID: DMM5SCF)

Drug Name
ONC201   DMM5SCF
Synonyms
Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
5 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glioma DIS5RPEH 2A00.0 Phase 2 [1]
Multiple myeloma DISEWP9B 2A83 Phase 2 [1]
Neuroendocrine cancer DISVGJET 2B72.1 Phase 2 [1]
Endometrial cancer DISW0LMR 2C76 Phase 2 [1]
Recurring respiratory infection DISG7AXL CA07-CA45 Phase 2 [1]
------------------------------------------------------------------------------------
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
leukaemia DISS7D1V 2A60-2B33 Phase 1/2 [1]
Lymphoma DISN6V4S 2A80-2A86 Phase 1/2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)